1283095-47-5

Basic information

• Product Name: Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro-
• Synonyms: Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro-;4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran];EOS-61591;spiro[4,5-dihydrothieno[2,3-c]pyran-7,4-piperdine 95%
• CAS NO: 1283095-47-5
• Molecular Formula: C₁₁H₁₅NOS
• Molecular Weight: 209.3079
• Mol File: 1283095-47-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro-(1283095-47-5)
• EPA Substance Registry System: Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro-(1283095-47-5)

Safety Data

• Hazardous Substances Data: 1283095-47-5(Hazardous Substances Data)

Usage

General Description

Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro- is a chemical compound with a unique structure that includes a spiro ring system, a piperidine ring, and a thieno[2,3-c]pyran ring. Spiro[piperidine-4,7'-[7H]thieno[2,3-c]pyran], 4',5'-dihydro- is in the dihydro form, meaning that it contains two hydrogen atoms in its structure. Spiro compounds are known for their diverse biological activities, and this particular compound may have potential pharmacological applications. Further research is needed to fully understand its properties and potential uses.

Upstream product

• 1307248-40-3 4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-ium trifluoroacetate 
• 13781-67-4 3-(2-hydroxyethyl)thiophene 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 1398399-65-9 1-benzyl-4′,5′-dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran] 
• 6964-21-2 thiophen-3-yl-acetic acid 
• 41979-39-9 4-piperidone hydrochloride 

Downstream Products

• 1283095-48-6 tert-butyl-4′,5′-dihydro-1H-spiro[piperidine-4,7′-thieno[2,3-c]pyran]-1-carboxylate 
• 1307248-42-5 2'-chloro-4',5'-dihydrospiro[piperidine-4,7'-thieno[2,3-c]pyran] hydrochloride 
• 1307245-86-8 [2-[4-[(2-chloro-4,4-difluoro-spiro[5H-thieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)methyl]-3-methyl-pyrazol-1-yl]-3-pyridyl]methanol 
• 1307248-45-8 tert-butyl 2′-chloro-4′,5′-dihydrospiro-[piperidine-4,7′-thieno[2,3-c]pyran]-1-carboxylate 
• 1283095-52-2 tert-butyl 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoate 
• 1307250-00-5 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanoic acid trifluoroacetate 
• 1307249-95-1 3-(2'-fluoro-4',5'-dihydro-1H-spiro[piperidine-4,7'-thieno[2,3-c]pyran]-1-yl)2-(2-fluorobenzyl)-N,N-dimethylpropanamide 
• 1283095-56-6 2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-isopropylpropanamide 
• 1283095-65-7 (2R)-2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-isopropylpropanamide 
• 1283095-62-4 (2S)-2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)-N-isopropylpropanamide 
• 1283095-66-8 (2R)-2-[(2-chlorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanamide 
• 1283095-63-5 (2S)-2-[(2-chlorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanamide 
• 1283095-67-9 (2R)-2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanamide 
• 1283095-64-6 (2S)-2-[(2-fluorophenyl)methyl]-3-(2-fluorospiro[4,5-dihydrothieno-[2,3-c]pyran-7,4'-piperidine]-1'-yl)propanamide 

Relevant articles and documents

Synthesis of an ORL-1 Receptor Antagonist via a Radical Bromination and Deoxyfluorination to Afford a gem-Difluorospirocycle

The development of a synthesis of an ORL-1 receptor antagonist is described. The key process improvements in the synthetic sequence include a multikilogram bromination process and the development of a convergent coupling strategy. The process improvements resulted in the production of the active pharmaceutical ingredient (API) on a multikilogram scale.

Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography

Positron emission tomography (PET) coupled to an effective radioligand could provide an important tool for understanding possible links between neuropsychiatric disorders and brain NOP (nociceptin/orphanin FQ peptide) receptors. We sought to develop such a PET radioligand. High-affinity NOP ligands were synthesized based on a 3-(2′-fluoro-4′,5′- dihydrospiro[piperidine-4,7′-thieno[2,3-c]pyran]-1-yl)-2(2-halobenzyl) -N-alkylpropanamide scaffold and from experimental screens in rats, with ex vivo LC-MS/MS measures, three ligands were identified for labeling with carbon-11 and evaluation with PET in monkey. Each ligand was labeled by 11C-methylation of an N-desmethyl precursor and studied in monkey under baseline and NOP receptor-preblock conditions. The three radioligands, [11C](S)-10a-c, gave similar results. Baseline scans showed high entry of radioactivity into the brain to give a distribution reflecting that expected for NOP receptors. Preblock experiments showed high early peak levels of brain radioactivity, which rapidly declined to a much lower level than seen in baseline scans, thereby indicating a high level of receptor-specific binding in baseline experiments. Overall, [11C](S)-10c showed the most favorable receptor-specific signal and kinetics and is now selected for evaluation in human subjects.

SPIROPIPERIDINE COMPOUNDS AS ORL-1 RECEPTOR ANTAGONISTS

An ORL-1 receptor antagonist of the formula: its uses, and methods for its preparation are described. ORL-1 antagonists are deemed to be useful in the treatment of depression and/or the treatment of overweight, obesity, and/or weight maintenance post treatment for overweight or obesity. Certain compounds have also demonstrated through animal models that the compounds of the present invention are useful for the treatment of migraines.